Have a feature idea you'd love to see implemented?
Let us know!
SABS SAB Biotherapeutics Inc
Price (delayed)
$3.55
Market cap
$32.76M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$6.29
Enterprise value
$28.11M
Highlights
The company's debt fell by 15% QoQ and by 2.8% YoY
SAB Biotherapeutics's equity has surged by 142% YoY but it has decreased by 20% QoQ
SAB Biotherapeutics's net income has shrunk by 67% YoY and by 13% QoQ
SAB Biotherapeutics's gross profit has shrunk by 63% YoY and by 46% QoQ
Key stats
What are the main financial stats of SABS
Market
Valuations
Earnings
Shares outstanding
9.23M
Market cap
$32.76M
Enterprise value
$28.11M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.89
Price to sales (P/S)
21.73
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
18.58
Revenue
$1.51M
Gross profit
$1.51M
Net income
-$45.57M
EBIT
-$45.24M
EBITDA
-$40.29M
Free cash flow
-$38.56M
Per share
Balance sheet
Liquidity
EPS
-$6.29
EPS diluted
-$6.29
Free cash flow per share
-$4.16
Book value per share
$4
Revenue per share
$0.16
TBVPS
$5.81
Total assets
$53.8M
Total liabilities
$16.89M
Debt
$4.52M
Equity
$36.9M
Working capital
$23.72M
Debt to equity
0.12
Current ratio
3.69
Quick ratio
3.45
Net debt/EBITDA
0.12
Margins
Efficiency
Dividend
EBITDA margin
-2,663.5%
Gross margin
100%
Net margin
-3,012.3%
Operating margin
-3,422.7%
Return on assets
-67.3%
Return on equity
-94.4%
Return on invested capital
-113.3%
Return on capital employed
-100.6%
Return on sales
-2,990.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SABS stock price
How has the SAB Biotherapeutics stock price performed over time
Intraday
-3.01%
1 week
-6.58%
1 month
-12.99%
1 year
-40.64%
YTD
-6.44%
QTD
-6.44%
Financial performance
How have SAB Biotherapeutics's revenue and profit performed over time
Revenue
$1.51M
Gross profit
$1.51M
Operating income
-$51.78M
Net income
-$45.57M
Gross margin
100%
Net margin
-3,012.3%
The operating margin has dropped by 108% since the previous quarter
The company's net margin has shrunk by 108% QoQ
SABS's operating income has plunged by 91% YoY and by 13% from the previous quarter
SAB Biotherapeutics's net income has shrunk by 67% YoY and by 13% QoQ
Growth
What is SAB Biotherapeutics's growth rate over time
Valuation
What is SAB Biotherapeutics stock price valuation
P/E
N/A
P/B
0.89
P/S
21.73
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
18.58
The EPS has decreased by 12% YoY and by 2.4% QoQ
SAB Biotherapeutics's equity has surged by 142% YoY but it has decreased by 20% QoQ
The P/B is 27% above the last 4 quarters average of 0.7
SAB Biotherapeutics's revenue has shrunk by 63% YoY and by 46% QoQ
The P/S is 45% above the last 4 quarters average of 15.0
Efficiency
How efficient is SAB Biotherapeutics business performance
The ROS has shrunk by 108% QoQ
The ROE has grown by 22% YoY
SAB Biotherapeutics's ROIC has increased by 3.9% YoY
SABS's ROA is up by 2.7% YoY but it is down by 2.4% from the previous quarter
Dividends
What is SABS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SABS.
Financial health
How did SAB Biotherapeutics financials performed over time
The company's total assets has surged by 90% YoY but it fell by 13% QoQ
SABS's current ratio is down by 30% since the previous quarter
The company's debt is 88% lower than its equity
SAB Biotherapeutics's equity has surged by 142% YoY but it has decreased by 20% QoQ
SABS's debt to equity has dropped by 60% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.